Meningococcal vaccines market seen reaching $6.48 billion by 2035

Market Research Future projects the global meningococcal vaccines market will grow from $3.59 billion in 2026 to $6.48 billion by 2035, driven by pentavalent vaccine launches, elimination-roadmap funding and expanding adolescent immunization mandates. The biggest shift is a move from multi-visit schedules to single-appointment coverage, which could lift completion rates and reshape procurement, manufacturing and competition. Why it matters: - Pentavalent vaccines are changing how meningococcal protection is delivered, which could improve series completion and expand overall dose volumes. - Routine immunization policy, outbreak response and travel requirements are turning the market into a steadier, more predictable revenue stream. - Low-cost manufacturing is widening access in high-burden regions and strengthening supply for global public-sector procurement. What happened: - Market Research Future said the global meningococcal vaccines market is projected to rise from $3.59 billion in 2026 to $6.48 billion by 2035. - The forecast implies a 7.62% compound annual growth rate from 2026 to 2035. - The market was estimated at $3.34 billion in 2025. - GSK’s Penmenvy received FDA approval in February 2025 as a pentavalent conjugate meningococcal vaccine covering serogroups A, B, C, W and Y. - Pfizer launched Penbraya in October 2023 as the first pentavalent vaccine on the U.S. market. - The Serum Institute of India’s Men5CV was WHO-prequalified in 2024 and is priced below $3 per dose for Gavi-eligible countries. - Request a free sample from the report. The details: - Pentavalent vaccines combine five serogroups in one injection, reducing what had often been a two- or three-visit adolescent schedule. - CDC estimates cited in the release suggest single-visit pentavalent vaccination could raise U.S. 16-year-old series completion rates from 57% to more than 78%. - The release says that could translate into about 8 million incremental doses a year. - The WHO Global Roadmap to Defeat Meningitis by 2030 has helped mobilize more than $450 million in Gavi co-financing for bacterial meningitis prevention campaigns across Sub-Saharan Africa and South Asia. - Gavi allocated $200 million in March 2024 to target 80 million doses across 15 eligible countries by 2027. - The release says 32 U.S. states now require at least one MenACWY dose for school admission. - More than a dozen states or university systems require serogroup B meningococcal protection or risk disclosures for college enrollment. - Chile procured 1.4 million extra MenACWY doses between 2022 and 2024 outside its routine schedule. - Quadrivalent vaccines held about 57% of revenue in 2025, while pentavalent vaccines were the fastest-growing product type at 9.10% CAGR. - Pentavalent vaccines are expected to capture more than 35% of global doses by 2030, up from under 5% in 2025. - Bivalent vaccines are projected to grow at 8.59% CAGR, and monovalent vaccines accounted for $0.28 billion in 2025. - Conjugate vaccines held 49% of the market in 2025, and combination vaccines are forecast to grow at 8.72% CAGR. - Public-sector sales accounted for 72% of revenue in 2025, while private-sector sales are projected to grow at 8.78% CAGR. - Children and adults age 2 and older represented 80% of revenue in 2025, while infants are the fastest-growing age group at 8.82% CAGR. - North America held about 43% of the market in 2025, with the U.S. generating about 82% of regional revenue. - Europe held about 27% of the market in 2025, with the U.K., Germany, France and Spain driving demand. - Asia-Pacific is projected to grow at 8.92% CAGR, making it the fastest-growing region. - Saudi Arabia led the Middle East and Africa market, while Brazil anchored South America. - The top five players controlled roughly 72% of global revenue, and the market’s estimated HHI was about 2,200. - GSK and Pfizer lead the pentavalent shift, Sanofi remains strong in quadrivalent vaccines and the Serum Institute is competing on price. - GSK and Pfizer’s launches have triggered more than $1.2 billion in cumulative R&D commitments from the top five manufacturers since 2023. Between the lines: - The market’s growth is being driven less by episodic outbreaks and more by structural policy shifts, which usually supports more durable demand. - Pentavalent products are likely to pressure legacy quadrivalent brands as formularies and reimbursement systems adjust. - The Serum Institute’s low-cost Men5CV could accelerate uptake in Gavi-eligible countries by lowering access and cold-chain barriers. - mRNA-based meningococcal candidates are still early, but they could eventually shorten the response time to new strains if regulators create an expedited pathway. - Mid-tier manufacturers without pentavalent technology may face margin pressure or need to license new platforms. What’s next: - Gavi’s next replenishment cycle from 2026 to 2030 is expected to allocate more than $600 million to bacterial meningitis prevention. - Pentavalent vaccines are projected to account for more than 35% of global doses by 2030. - GSK and Pfizer are expected to exceed a combined 45% global share by decade-end. - India’s possible inclusion of meningococcal vaccination in its Universal Immunization Programme could add 26 million doses annually. - Clinical licensure of mRNA-based meningococcal products before 2033 is considered unlikely, leaving conjugate and recombinant protein platforms dominant for most of the forecast period. - Read the detailed report The bottom line: - The meningococcal vaccines market is moving toward broader coverage, fewer doses per visit and stronger public-sector purchasing, with pentavalent vaccines set to reshape both demand and competition.